Get started
NOVAVAX INCNOVAVAX INCNOVAVAX INC

NOVAVAX INC

No trades
See on Supercharts
Overview
Financials News Ideas Discussions Technicals Forecast Seasonals Bonds

NVV1 chart


Full chart

Key facts today

Novavax's CEO stated that U.S. COVID-19 vaccine demand may hit 40 to 50 million doses this season. The company is also considering selling its manufacturing plant in the Czech Republic.
Analyze the impactAnalyze the impact

NVV1 upcoming earnings

Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪1.35 B‬ EUR
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−2.490 EUR
Net income (FY)
‪−493.83 M‬ EUR
Revenue (FY)
‪891.25 M‬ EUR
Shares float
‪153.03 M‬
Beta (1Y)
2.00

Employees


Employees (FY)
‪1.54 K‬
Change (1Y)
−449 −22.54%
Revenue / Employee (1Y)
‪637.53 K‬ EUR
Net income / Employee (1Y)
‪−353.25 K‬ EUR

About Novavax, Inc.


Sector
Health Technology
Industry
Biotechnology
CEO
John C.s Jacobs
Website
novavax.com
Headquarters
Gaithersburg
Founded
1987
FIGI
BBG000N2H910
Novavax, Inc. Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—
‪0.00‬

NVV1 news



Ideas



See all ideas 

Technicals

Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

NVV1 highest yielding bonds


NVAX5729297
Novavax, Inc. 5.0% 15-DEC-2027
Yield to maturity
2.83%
Maturity date
Dec 15, 2027

Explore more bonds 

Sparks


Curated watchlists where NVV1 is featured.

See all sparks 

Frequently Asked Questions


The current price of NVV1 is 7.971 EUR — it has decreased by −6.68% in the past 24 hours. Watch NOVAVAX INC stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on FWB exchange NOVAVAX INC stocks are traded under the ticker NVV1.
NVV1 stock has fallen by −4.33% compared to the previous week, the month change is a −31.90% fall, over the last year NOVAVAX INC has showed a 35.93% increase.
We've gathered analysts' opinions on NOVAVAX INC future price: according to them, NVV1 price has a max estimate of 24.48 EUR and a min estimate of 8.47 EUR. Watch NVV1 chart and read a more detailed NOVAVAX INC stock forecast: see what analysts think of NOVAVAX INC and suggest that you do with its stocks.
NVV1 reached its all-time high on Feb 8, 2021 with the price of 274.150 EUR, and its all-time low was 3.300 EUR and was reached on Nov 21, 2019. View more price dynamics on NVV1 chart.
See other stocks reaching their highest and lowest prices.
NVV1 stock is 21.35% volatile and has beta coefficient of 2.00. Track NOVAVAX INC stock price on the chart and check out the list of the most volatile stocks — is NOVAVAX INC there?
Today NOVAVAX INC has the market capitalization of ‪1.36 B‬, it has decreased by −0.87% over the last week.
Yes, you can track NOVAVAX INC financials in yearly and quarterly reports right on TradingView.
NOVAVAX INC is going to release the next earnings report on Mar 4, 2025. Keep track of upcoming events with our Earnings Calendar.
NVV1 earnings for the last quarter are −0.68 EUR per share, whereas the estimation was −0.71 EUR resulting in a 3.93% surprise. The estimated earnings for the next quarter are −0.19 EUR per share. See more details about NOVAVAX INC earnings.
NOVAVAX INC revenue for the last quarter amounts to ‪75.90 M‬ EUR, despite the estimated figure of ‪66.27 M‬ EUR. In the next quarter, revenue is expected to reach ‪173.43 M‬ EUR.
NVV1 net income for the last quarter is ‪151.60 M‬ EUR, while the quarter before that showed ‪−136.75 M‬ EUR of net income which accounts for 210.86% change. Track more NOVAVAX INC financial stats to get the full picture.
No, NVV1 doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Nov 13, 2024, the company has ‪1.54 K‬ employees. See our rating of the largest employees — is NOVAVAX INC on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. NOVAVAX INC EBITDA is ‪−224.59 M‬ EUR, and current EBITDA margin is −38.00%. See more stats in NOVAVAX INC financial statements.
Like other stocks, NVV1 shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade NOVAVAX INC stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So NOVAVAX INC technincal analysis shows the strong sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating NOVAVAX INC stock shows the sell signal. See more of NOVAVAX INC technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.